Experiment 68694
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Salix purpurea (SALICACEAE) |
| Citation | SCHMID,B: KOTTER,I: HEIDE,L:. (2001). PHARMACOKINETICS OF SALICIN AFTER ORAL ADMINISTRATION OF A STANDARDISED WILLOW BARK EXTRACT.. 57(5) |
| Amount utilized | |
| Compound isolated | |
| Disease | TO EVALUATE THE PHARMACOKINETIS OF SALICIN AND ITS MAJOR METABOLITES IN HUMANS AFTER ORAL ADMINISTRATION OF A CHEMICALLY STANDARDISED WILLOW BARK EXTRACT. WILLOW BARK EXTRACT CORRESPONDING TO 240 MG SALICIN (1360 MG, 838 UMMOL) WAS INGESTED BY TEN HEALTHY VOLUNTEERS IN TWO EQUAL DOSES AT TIMES 0 H AND 3 H. OVER A PERIOD OF 24 H, URINE AND SERUM LEVELS OF SALICYLIC ACID AND ITS METABOLITIES, I.E. GENTISIC ACID AND SALICYLURIC ACID, WERE DETERMINED USING REVERSE-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY. RENAL EXCRETION RATE, ELIMINATION HALF-LIFE AND TOTAL BIOAVAILABILITY OF SALICYLATES WERE CALCULATED. SALICYLIC ACID WAS THE MAJOR METABOLITES OF SALICIN DETECTED IN THE SERUM (86% OF TOTAL SALICYLATES), BESIDES SALICYLURIC ACID (10%) AND GENTISIC ACID (4%). PEAK LEVELS WERE REACHED WITHIN LESS THAN 2 H AFTER ORAL ADMINISTRATION. RENAL ELIMINATION OCCURRED PREDOMINANTLY IN THE FORM OF SALICYLURIC ACID. PEAK SERUM LEVELS OF SALICYCLIC ACID WERE ON AVERAGE 1.2 MG/1, AND THE OBSERVED AREA UNDER THE SERUM CONCENTRATION-TIME CURVE (AUC) OF SALICYCLIC ACID WAS EQUIVALENT TO THAT EXPECTED FROM AN INTAKE OF 87 MG ACETYLSALICYLIC ACID. WILLOW BARK EXTRACT IN THE CURRENT THERPAEUTIC DOSE LEADS TO MUCH LOWER SERUM SALICYLATE LEVELS THAN OBSERVED AFTER ANALGESIC DOSES OF SYNTHETIC SALICYLATES. THE FORMATION OF SALICYLIC ACID ALONE IS THEREFORE UNLIKELY TO EXPLAIN ANALGESIC OR ANTI-RHEUMATIC EFFECT OF WILLOW BARK. |
| Dose amount | 240.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | TYPE EXT NOT STATED |
| Gender | GIVEN TO BOTH SEXES |